Paul E. Oberstein, MD, discusses a personalized mRNA vaccine being evaluated in pancreatic ductal adenocarcinoma and why it matters.
Back
Exploring RNA Neoantigen Vaccines in Pancreatic Cancer
Paul E. Oberstein, MD, breaks down research for the mRNA vaccine autogene cevumeran in pancreatic cancer.
Exploring RNA Neoantigen Vaccines in Pancreatic Cancer
Episodes
All
All
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Paul E. Oberstein, MD, discusses data for an autogene cevumeran–based regimen in pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
2
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma
3
Cevostamab Plus Pomalidomide/Dexamethasone Yields Durable, Deep Responses in BCMA-Naive Relapsed/Refractory Myeloma
4
FDA MCGP Panel Vote Backs Galleri Multi-Cancer Early Detection Test
5